Azalea Vision Secures Up to €7.5 Million from European Innovation Council to Advance Smart Contact Lens Platform Toward Clinical Development
Belgian health technology innovator Azalea Vision has secured a major boost for the development of its pioneering smart contact lens technology after being selected for the prestigious European Innovation Council (EIC) Accelerator, one of Europe’s most competitive funding initiatives for breakthrough deep-tech companies. The selection positions Azalea Vision among an elite group of startups recognized for their potential to transform healthcare through disruptive innovation.
As part of the award, the company will receive funding of up to €7.5 million, consisting of a non-dilutive €2.5 million grant together with a planned €5 million equity investment from the EIC Fund. The financing will support the continued advancement of Azalea Vision’s proprietary medical-grade smart contact lens platform as it moves into clinical development and progresses toward commercialization.
The announcement represents more than a financial milestone. It serves as a strong endorsement from one of Europe’s leading innovation bodies, recognizing both the technological sophistication of Azalea Vision’s platform and its long-term commercial potential within the global medical device market.
Recognition from Europe’s Premier Deep-Tech Funding Program
The European Innovation Council Accelerator is regarded as one of the world’s most selective funding programs for high-impact technology companies. Operating under the European Union’s Horizon Europe framework, the initiative supports startups and small businesses developing groundbreaking innovations capable of creating entirely new markets or disrupting existing industries.
Competition for funding is exceptionally intense, with fewer than five percent of applicants successfully navigating the rigorous evaluation process. Applicants undergo multiple rounds of technical assessments, business evaluations, and interviews conducted by independent experts and industry leaders before final selections are made.
In this latest funding round, Azalea Vision emerged as the only Belgian company selected, highlighting both the company’s technological leadership and Belgium’s growing role within Europe’s medtech innovation ecosystem.
Unlike many traditional grant programs, the EIC Accelerator combines grant funding with direct equity investment through the EIC Fund. This dual approach means that the European Union not only supports research and development but also becomes a long-term investor in companies demonstrating exceptional commercial promise.
Because the EIC Fund commits its own capital alongside grant financing, selection is widely viewed as an important validation of a company’s technology, business strategy, and market opportunity. Such recognition can significantly improve a company’s ability to attract additional private investment while reducing perceived risks for future investors.
Advancing the World’s First Medical-Grade Smart Contact Lens
At the center of Azalea Vision’s innovation strategy is the development of what the company describes as the first medical-grade smart contact lens.
The technology has been designed to address several significant unmet medical needs affecting millions of people worldwide who experience impaired vision resulting from complex eye conditions.
Initially, the company’s smart lens platform is intended to improve vision for patients living with:
- Irregular corneas
- Higher-order optical aberrations
- Presbyopia, the age-related decline in near vision
Unlike conventional contact lenses that simply correct refractive errors such as nearsightedness or farsightedness, Azalea Vision’s platform aims to provide sophisticated optical correction for conditions that often remain difficult to manage using existing solutions.
The company believes its technology could substantially improve quality of life by delivering more personalized visual correction while maintaining the comfort and convenience associated with contact lenses.
Beyond Vision Correction
While vision enhancement represents the company’s first clinical objective, Azalea Vision’s platform has significantly broader ambitions.
The same smart contact lens technology is being developed to function as a future biosensing platform, capable of monitoring biomarkers contained within human tears.
Tear fluid is increasingly recognized by researchers as an important diagnostic source because it contains numerous biological molecules that may reflect changes in human health. Since tears can be collected non-invasively, they present attractive opportunities for continuous health monitoring without requiring blood draws or invasive testing.
Azalea Vision believes its technology could eventually support the measurement of a wide range of biomarkers directly through the contact lens, potentially enabling new approaches for disease monitoring and personalized healthcare.
Such capabilities could open opportunities well beyond ophthalmology, expanding the platform into digital health, diagnostics, and continuous physiological monitoring.
Funding to Accelerate Clinical Development
The newly awarded EIC funding will primarily support the next stage of product development as the company transitions from engineering and technical validation into clinical studies.
According to Azalea Vision, much of the core functionality of its smart contact lens platform has already been established, while technical validation activities are nearing completion.
The funding will help finance:
- Clinical development activities
- Final engineering optimization
- Product validation
- Regulatory preparation
- Advancement toward medical certification
These milestones represent critical steps before the technology can ultimately become available to patients.
The combination of grant funding and equity investment provides the company with financial flexibility while minimizing shareholder dilution during one of the most resource-intensive stages of medical device development.
External Validation of Technology and Vision
Company leadership emphasized that selection by the European Innovation Council represents independent recognition of years of scientific and engineering work.
According to Andrés Vasquez Quintero, Co-founder and Chief Technology Officer of Azalea Vision, the award validates both the technological foundation of the company and the scale of the opportunity ahead.
He noted that the EIC Accelerator is among the most demanding innovation funding programs globally, making the company’s selection particularly meaningful.
Vasquez Quintero explained that Azalea Vision has reached an important point where its core platform has demonstrated strong technical performance. With technical validation approaching completion, the company is now preparing to generate clinical evidence needed to support regulatory approval and commercial deployment.
He added that the new funding provides the resources necessary to rapidly transition from a proven technology platform into clinical evaluation while continuing development within Europe.
Supporting Europe’s Medical Technology Ecosystem
The award also reflects broader European efforts to strengthen the continent’s leadership in advanced medical technologies.
Through programs such as the EIC Accelerator, the European Union aims to ensure that innovative companies can continue developing transformative healthcare technologies within Europe rather than relocating elsewhere in search of investment.
By combining grant support with direct investment, the EIC seeks to bridge one of the most challenging phases of technology commercialization—moving from successful laboratory innovation to clinical validation and market readiness.
For companies developing highly regulated medical technologies, this transition often requires substantial financial resources over several years before products generate commercial revenue.
Opening New Investment Opportunities
Beyond providing immediate funding, the EIC Accelerator selection is expected to strengthen Azalea Vision’s ability to attract additional investment.
The company has indicated that it is now beginning discussions with both strategic partners and financial investors across Europe and the United States regarding participation in its upcoming financing round.
Because the EIC Fund invests alongside private investors, its involvement is often viewed as a strong signal of confidence that can encourage additional institutional participation.
Azalea Vision expects the combination of public and private investment to accelerate product development while supporting long-term commercialization plans.
Building a Next-Generation Medical Device Company
Looking ahead, Azalea Vision plans to use the EIC funding as a catalyst for its next phase of growth.
With engineering work nearing completion, the company’s immediate priorities include completing clinical studies, advancing regulatory development, and preparing the platform for future commercialization.
At the same time, management continues to pursue the longer-term vision of expanding the smart contact lens beyond vision correction into biosensing applications that could reshape how patients monitor their health.
By combining advanced optics, wearable medical technology, and future diagnostic capabilities within a single platform, Azalea Vision aims to establish itself as a leader in next-generation ophthalmic and digital health innovation.
The company’s selection by the European Innovation Council not only provides significant financial resources but also places it among Europe’s most promising emerging deep-tech companies. As clinical development progresses, the funding is expected to accelerate the journey toward bringing a novel medical-grade smart contact lens to patients while reinforcing Europe’s position as a global center for breakthrough medical device innovation.
About Azalea Vision
Azalea Vision is a Belgian healthtech company developing the first medical-grade smart lens platform designed to sense, adapt and connect in real time. Its lens-embedded system integrates adaptive optics, custom microelectronics, liquid-crystal technology and connectivity to address vision conditions and enable tear-based health monitoring. Founded in 2021 as a spin-off from imec and Ghent University, Azalea Vision is advancing smart lens technology toward clinical translation.
